National multicentric evaluation of quality of pathology reports for rectal cancer in France in 2016.


Journal

Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843

Informations de publication

Date de publication:
May 2019
Historique:
received: 19 10 2018
accepted: 28 01 2019
revised: 07 01 2019
pubmed: 8 2 2019
medline: 17 5 2019
entrez: 8 2 2019
Statut: ppublish

Résumé

The quality of pathologic assessment of rectal cancer specimens is crucial for treatment efficiency and survival. The Royal College of Pathologists (RCP) recommends evaluating the quality of the pathology report in routine practice using three quality indicators (QIs): the number of lymph nodes (LNs) analyzed (≥ 12), the rate of venous invasion (VI ≥ 30%), and peritoneal involvement (pT4a ≥ 10%). In this study, we evaluated the three QIs of the French national pathology reports and compared them with British guidelines and assessed the influence of neoadjuvant radiochemotherapy on QIs. From January 1 to December 31, 2016, all pathology reports for rectal adenocarcinoma were collected from French departments. Neoadjuvant radiochemotherapy included long-course radiotherapy with concomitant 5-FU-based chemotherapy. A total of 983 rectal cancer pathology reports were evaluated. A median of 15 LNs were analyzed and 81% of centers had ≥ 12 LNs. The rate of VI was 30% and 41% of centers had ≥ 30% VI. The rate of pT4a was 4% and 18% of centers reported ≥ 10% pT4a. None of the centers reached the threshold for the three QIs. All three QIs were lower after radiochemotherapy compared to surgery alone. In conclusion, in French routine practice, the values of two of the three QIs (LNs analyzed and VI) were globally in line with RCP guidelines. However, the rate of pT4a was very low, particularly after radiochemotherapy, suggesting its low value in rectal cancer.

Identifiants

pubmed: 30729335
doi: 10.1007/s00428-019-02534-8
pii: 10.1007/s00428-019-02534-8
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

561-568

Auteurs

C Boutanos (C)

Department of Pathology, CHU Bordeaux, Place Amélie Raba-Léon, 33076, Bordeaux cedex, France.

M Capdepont (M)

Department of Pathology, CHU Bordeaux, Place Amélie Raba-Léon, 33076, Bordeaux cedex, France.

M Svrcek (M)

Department of Pathology, CHU Saint-Antoine APHP, 184 Rue du Faubourg Saint-Antoine, 75012, Paris, France.

F Thélu (F)

Pathologie Nord Unilabs, 60 Boulevard Jean-Baptiste Lebas, 59000, Lille, France.

N Guedj (N)

Department of Pathology, CHU Beaujon APHP, 100 Boulevard du Général Leclerc, 92110, Clichy, France.

F Poizat (F)

Department of Pathology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.

F Bibeau (F)

Department of Pathology, Institut du Cancer de Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.

B Turlin (B)

Department of Pathology, CHU Rennes, 2 Rue Henri le Guilloux, 35000, Rennes, France.

A Rousseau (A)

Biopath Aquitaine, 4 Allée des Musardises, 33185, Le Haillan, France.

A Bardier (A)

Department of Pathology, CHU de La Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013, Paris, France.

J Selves (J)

Department of Pathology, IUCT Oncopole, 1 Avenue Irène Joliot-Curie, 31100, Toulouse, France.

M Desrousseaux (M)

Atlantic Pathologie, 24 avenue du Général Ducasse, 64100, Bayonne, France.

F Le Pessot (F)

Service de Pathologie, CHU Rouen, 1 Rue de Germont, 76000, Rouen, France.

B Bonhomme (B)

Department of Pathology, Institut Bergonié, 229 Cours de l'Argonne, 33000, Bordeaux, France.

M-H Laverrière (MH)

Department of Pathology, CHU Grenoble, BP 217, 38043, Grenoble, France.

C Julié (C)

Department of Pathology, CHU Ambroise Paré APHP, 9 Avenue Charles de Gaulle, 92100, Boulogne-Billancourt, France.

R-P Eyremandi (RP)

Laboratoire d'Anatomie et de Cytologie Pathologiques, 43 Avenue Gaston Phoebus, 64000, Pau, France.

S Stanislas (S)

Department of Pathology, CH Pau, 4 Boulevard Hauterive, 64000, Pau, France.

C Bazille (C)

Department of Pathology, CHU Caen, Avenue de la Côte de Nacre, 14033, Caen, France.

A Daubech (A)

Cabinet de Pathologie, 259 Boulevard Godard, 33110, Le Bouscat, France.

T Lazure (T)

Department of Pathology, CHU Kremlin-Bicêtre, 78 Rue du Général Leclerc, 94270, Le Kremlin-Bicêtre, France.

M-S Bordier (MS)

Department of Pathology, CH Libourne, 112 Rue de la Marne, 33500, Libourne, France.

A Demoures (A)

Department of Pathology, CH Périgueux, 80 Avenue Georges Pompidou, 24000, Périgueux, France.

Anne Rullier (A)

Department of Pathology, CHU Bordeaux, Place Amélie Raba-Léon, 33076, Bordeaux cedex, France. anne.rullier@chu-bordeaux.fr.
CHU Pellegrin, Place Amélie Raba-Léon, 33000, Bordeaux, France. anne.rullier@chu-bordeaux.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH